Creo Medical Group (FRA:1RC) Beta: 1.9698 (As of Jun. 26, 2026)


FRA:1RC Creo Medical Group PLC FRA:1RC
53 GF Score
Price €0.15
GF Value €0.18
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Beta?

Creo Medical Group FRA:1RC 53 Beta is 1.9698 as of Jun. 26, 2026. GuruFocus rates FRA:1RC with a GF Score™ of 53/100 and a GF Value™ of €0.18. The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Creo Medical Group's Beta is 1.9698.


Creo Medical Group  (FRA:1RC) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Creo Medical Group Beta Related Terms


Creo Medical Group Beta Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group Beta Chart

Creo Medical Group Annual Data
Trend Feb15 Feb16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.38 -0.35 -0.70

Creo Medical Group Semi-Annual Data
Feb15 Feb16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.45 -0.35 0.34 -0.70

FRA:1RC vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, Creo Medical Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creo Medical Group Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Beta distribution charts can be found below:

* The bar in red indicates where Creo Medical Group's Beta falls into.


FRA:1RC
53GF Score
Creo Medical Group PLC FRA:1RC
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creo Medical Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.9698 mean?
Creo Medical Group (FRA:1RC) has a Beta of 1.9698 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Creo Medical Group and its competitors.
Is Creo Medical Group's Beta too high?
Creo Medical Group's current Beta is 1.9698. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Beta compare to ABT and SYK?
Creo Medical Group's Beta of 1.9698 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Creo Medical Group and its competitors. Creo Medical Group's current Beta is 1.9698. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (FRA:1RC) has a current Beta of 1.9698. The stock's GF Value™ is €0.18, compared to a current price of €0.15 — trading 18.9% below its estimated fair value. The current Beta is 1.9698. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Creo Medical Group (FRA:1RC), the current Beta is 1.9698 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (FRA:1RC) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of €0.15 is trading 18.9% below its estimated GF Value™ of €0.18.

Key valuation signals for FRA:1RC:

  • Beta: 1.9698
  • GF Value™: €0.18 vs. price of €0.15 (18.9% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the FRA:1RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score

Get the complete analysis for FRA:1RC

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.18
GF Value